Supplementary Materials

Supplementary Material for:

mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome

Rocco G. Gogliotti, Rebecca K. Senter, Nicole M. Fisher, Jeffrey Adams, Rocio Zamorano, Adam G. Walker, Anna L. Blobaum, Darren W. Engers, Corey R. Hopkins, J. Scott Daniels, Carrie K. Jones, Craig W. Lindsley, Zixiu Xiang, P. Jeffrey Conn, Colleen M. Niswender*

*Corresponding author. Email: colleen.niswender{at}

Published 16 August 2017, Sci. Transl. Med. 9, eaai7459 (2017)
DOI: 10.1126/scitranslmed.aai7459

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Antibody #07-239 is selective for mGlu7.
  • Fig. S2. Gad65, but not mGlu4, expression is reduced in Mecp2−/y mice.
  • Fig. S3. Mecp2−/y hippocampal slices display enhanced excitatory transmission at the SC-CA1 synapse.
  • Fig. S4. VU0155094, a PAM that is structurally distinct from VU0422288, also rescues the efficacy of LSP4-2022 on fEPSPs at SC-CA1 in Mecp2−/y slices.
  • Fig. S5. VU0422288 rescues attenuated LTP at the SC-CA1 synapse in Mecp2−/y mice.
  • Fig. S6. ADX88178 is active at mGlu4 and mGlu8, but not at mGlu7.
  • Fig. S7. Startle response threshold is not affected by VU0422288 and ADX88178 treatment in Mecp2+/+ or Mecp2+/− mice.
  • Fig. S8. Coadministration of VU0422288 and ADX71743 confirm mGlu7’s role in cognition but evokes sedative effects.
  • Fig. S9. Efficacy is conserved with repeated VU0422288 administration.
  • Table S1. Human motor cortex sample data.
  • Table S2. Pharmacokinetic analysis of VU0422288.

[Download PDF]